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Abstract 
Background: Both uremia and metabolic syndrome (MetS) affect heart rate variability (HRV) which is a risk factor 
of poor prognoses. The aim of this study was to evaluate the impact of MetS on HRV among chronic hemodialysis 
patients.
Methods: This cross‑sectional study was carried out in a teaching hospital in Northern Taiwan from June to August, 
2010. Adult patients on chronic hemodialysis without active medical conditions were enrolled. HRV were measured 
for 4 times on the index hemodialysis day (HRV‑0, ‑1, ‑2, and ‑3 at before, initial, middle, and late phases of hemodialy‑
sis, respectively), and the baseline demographic data and clinical parameters during the hemodialysis session were 
documented. Then we evaluated the impacts of MetS and its five components on HRV.
Results: One hundred and seventy‑five patients (100 women, mean age 65.1 ± 12.9 years) were enrolled and 
included those with MetS (n = 91, 52 %) and without MetS (n = 84, 48 %). The patients with MetS(+) had significantly 
lower very low frequency, total power, and variance in HRV‑0, total power and variance in HRV‑2, and variance in 
HRV‑3. (all p ≦ 0.05) When using the individual components of MetS to evaluate the impacts on HRV indices, the fast‑
ing plasma glucose (FPG) criterion significantly affected most indices of HRV while other four components including 
“waist circumference”, “triglycerides”, “blood pressure”, and “high‑density lipoprotein” criteria exhibited little impacts on 
HRV. FPG criterion carried the most powerful influence on cardiac ANS, which was even higher than that of MetS. The 
HRV of patients with FPG(+) increased initially during the hemodialysis, but turned to decrease dramatically at the 
late phase of hemodialysis.
Conclusions: The impact of FPG(+) outstood the influence of uremic autonomic dysfunction, and FPG criterion was 
the most important one among all the components of MetS to influence HRV. These results underscored the impor‑
tance of interpretation and management for abnormal glucose metabolism.
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Background
Metabolic syndrome (MetS), a clustering of risk factors, 
is associated with increased risk of developing cardio-
vascular diseases and diabetes mellitus (DM) [1]. While 
cardiac autonomic nervous system (ANS) dysfunction 
has been considered as a complication of MetS and a 
potential mediator linking MetS and adverse cardiovas-
cular events [2, 3]. Meanwhile, cardiac ANS dysfunction 
is also found in more than 50 percent of uremic patients 
treated with maintenance hemodialysis (HD) [4], in 
whom the autonomic neuropathy is resulted from the 
defect of baroreceptor, down-regulation of alpha-adren-
ergic receptors and inappropriately activation of Bezold-
Jarisch reflex [5].
Heart rate variability (HRV), which means variation 
of beat-to-beat interval, is a noninvasive way to evaluate 
ANS functions. During mild sympathetic stimulation, the 
HRV indices might increase. However, if the sympathetic 
stimulation is intense or prolonged, an overall decrease 
in HRV without correlation with the reduction in sym-
pathetic activity would be seen [6]. While reduced HRV 
is a significant risk factor for cardiac death, all-cause 
mortality, development of coronary artery disease and 
type 2 DM [2, 7, 8]. HRV measurement includes time 
domain and frequency domain analyses [9, 10]. Among 
the frequency domain indices, very low frequency (VLF) 
is thought to be influenced by the thermoregulation of 
vasomotor tone; low-frequency (LF) activity is widely 
recognized to reflect a mixture of both the sympathetic 
and parasympathetic tone; high-frequency (HF) activ-
ity has been linked to parasympathetic nervous activity, 
which is associated with the vagal-medicated modulation 
of heart rate; LF/HF ratio is an index of sympathovagal 
balance and thus of autonomic status or sympathetic 
nervous activities; total power (TP) can be estimated 
with the sum of the frequencies; whereas variance of the 
R–R interval values (Var) reflects all the cyclic compo-
nents responsible for variability in the period of record-
ing [10–15].
Previous studies has investigated the association 
between MetS and HRV in different participant groups 
including young adults [16], old adult [17], industrial 
workers [18], patients with intellectual disabilities [19] 
or schizophrenia [20], in addition to general population 
[21]. The results regarding the influence of MetS and 
the individual components on HRV indices were incon-
clusive. But generally speaking, the HRV indices tend to 
decrease in women with MetS comparing to those with-
out MetS, but the changes are inconsistent in men [22].
Nonetheless, the association of MetS and HRV has 
never been evaluated in chronic HD patients. The asso-
ciation between these two entities might be compli-
cated and different from that in other populations since 
the uremic autonomic neuropathy per se involves both 
sympathetic and parasympathetic pathways [23]. There-
fore, we conducted current study to elucidate the impact 
of MetS and its components on HRV at different phases 
of HD process, which might further evaluate the serial 




This cross-sectional study was conducted in a teaching 
hospital in Northern Taiwan, which was approved by the 
Institutional Review Board of Saint Mary Hospital Luo-
dong. Written informed consents were obtained from all 
participants, and the data was analyzed anonymously.
Study design and populations
Patients were eligible for enrollment if they were adults 
who underwent maintenance HD with stable conditions 
during the period from June to August, 2010. Exclusion 
criteria included patients who were less than 18 years of 
age, who received HD for less than 3  months, who had 
arrhythmia or active infection, or who were not willing 
to receive HRV measurement. Enrolled patients were 
arranged to receive HRV measurements before HD 
(HRV-0, as baseline data), and three times during HD 
(HRV-1, -2, and -3 at initial, middle, and late phases of 
the index HD session, respectively).
The baseline demographic data, comorbid diseases, 
etiologies of uremia, and medications were documented 
from patients’ medical charts. The clinical parameters 
included blood tests such as complete blood cell count, 
blood urea nitrogen, serum creatinine, calcium, phos-
phate, albumin, sodium, potassium, sugar, glycated 
hemoglobin, intact-parathyroid hormone, and lipid pro-
files, as well as cardiothoracic ratio were recorded at the 
time of HRV measurement.
MetS is defined as the presence of any three of the five 
components: (1) a waist circumference (WC) ≧90 cm (in 
men) and ≧80  cm (in women); (2) blood pressure (BP) 
≧130/85  mmHg or drug treatment for elevated blood 
pressure; (3) fasting plasma glucose (FPG) ≧100  mg/dl 
or drug treatment for elevated blood sugar; (4) serum 
triglycerides (TG) ≧150  mg/dl or drug treatment for 
elevated triglycerides; (5) serum high-density lipoprotein 
(HDL) <40  mg/dl (in men) and <50  mg/dl (in women) 
or drug treatment for low HDL [24]. Other definitions 
were made as followings: DM, previous usage of insulin 
or oral hypoglycemic agents; hypertension, usage of anti-
hypertension agents or pre-dialysis BP >140/90 mmHg in 
more than half of the records within the recent 1 month; 
[25] heart failure, New York Heart Association functional 
class III or IV.
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Then we categorized all participants according to pres-
ence or absence of MetS and its five components, and 
compared the demographic characteristics and the serial 
HRV indices during HD between (or among) the groups, 
to evaluate the impacts of MetS and its five components 
on the individual parameters of HRV before and during 
HD process.
Measurements of HRV
HRVs were measured using an analyzer (SSIC, Enjoy 
Research Inc., Taiwan). It took 5 min while the patients 
lay quietly with normal breath for more than 20  min. 
Under a sampling rate of 512  Hz, signals from a lead I 
electrocardiogram were documented by an 8-bit analog-
to-digital converter. Fast Fourier transformation was uti-
lized to perform power spectral analysis which quantified 
power spectrum into the standard frequency-domain 
measurements including VLF (0.003–0.04 Hz), LF (0.04–
0.15 Hz), HF (0.15–0.40 Hz), TP, LF/HF ratio, and Var  [9, 
10].
Statistical analysis
The statistical analyses were performed using the Sci-
entific Package for Social Science (PASW Statistics for 
Windows, Version 18.0, Chicago: SPSS Inc). Chi square 
test was used whenever appropriate for comparing cat-
egorical variables between two groups. Independent and 
paired student’s t test were performed to evaluate the 
differences in continuous and non-normally distributed 
variables between two groups and between different time 
points during HD in the same group, respectively. Two-
way analysis of variance (ANOVA) were performed to 
evaluate the differences in continuous variables among 
the four groups (FPG(+)/MetS(+), FPG(+)/MetS(−), 
FPG(−)/MetS(+), FPG(−)/MetS(−)), while Post Hoc 
multiple comparison with Bonferroni method for equal 
variances assumption were further undertaken for 
group-to-group analysis. Microsoft Office Excel 2013 was 
used to draw the plots comparing the serial HRV indi-
ces among groups. Continuous data were expressed as 
mean ± standard deviation, whereas categorical variables 
were shown as number (percentage) unless otherwise 
specified. In all statistical analyses, two-sided p ≦  0.05 
was considered statistically significant.
Results
During the study period from June to August, 2010, 202 
patients who underwent HD for more than 3  months 
were screened. After excluding 7 patients with infec-
tious disease, 14 patients with obvious arrhythmia, 
and 6 patients who hesitated to receive HRV meas-
urement, a total of 175 patients (100 women, mean 
age 65.1  ±  12.9  years) were enrolled. According to the 
definitions of MetS and its components, 91 (52.0  %) 
patients were diagnosed with MetS (MetS(+)), while 79 
(45.1 %) patients were WC(+), 128 (73.1 %) were BP(+), 
65 (37.1  %) were FPG(+), 63 (36.0  %) were TG(+), 
and 125 (71.4  %) were HDL(+). As to the associations 
between MetS and its five components, the diagnosis of 
MetS was established in 78.5 % of patients with WC(+), 
52.3  % of patients with BP(+), 83.1  % of patients with 
FPG(+), 87.3  % of patients with TG(+), and 69.6  % of 
patients with HDL(+).
Comparisons of demographic data between participants 
with and without MetS
The clinical characteristics of all participants, along with 
MetS(+) and MetS(−) groups were shown in Table 1. The 
most frequent cause of uremia in MetS(+) and MetS(−) 
groups were diabetic nephropathy (51.6  %) and chronic 
glomerulonephritis (67.9  %), respectively. Comparing 
with the MetS(−) group, those in MetS(+) group had 
significantly higher portion of DM (51.6 % versus 9.5 %, 
p < 0.001), higher WC (90.1 versus 81.1 cm, p < 0.001), 
along with higher serum TG (208.0 versus 103.5 mg/dL, 
p < 0.001) and LDL (105.2 versus 90.5 mg/dL, p = 0.001) 
levels. The MetS(+) group also had lower HDL (25.0 ver-
sus 47.2  mg/dL, p  <  0.001) and intact-parathyroid hor-
mone (i-PTH, 204.7 versus 373.1  μg/L, p  =  0.025). As 
to the HD-associated parameters, the MetS(+) group 
had worse dialysis clearance (Kt/V, 1.37 versus 1.50, 
p  <  0.001), but higher dry weight (63.5 versus 51.4  kg, 
p = 0.007) and baseline BP including systolic BP-0 (134.2 
versus 123.4 mmHg, p = 0.006), and mean arterial pres-
sure (93.1 versus 87.7 mmHg, p =  0.036). Other demo-
graphic and clinical parameters were not statistically 
different between the two groups (Table 1).
Impact on HRV: from MetS and its five components
The impacts of MetS and its five components on the 
HRV indices at different phases of HD were summa-
rized in Tables 2 and 3. We found that the patients with 
MetS(+) had significantly lower VLF-0 (4.16  ±  1.79 
versus 4.88  ±  1.53, p  =  0.027), TP-0 (4.16  ±  1.79 ver-
sus 5.77  ±  1.72, p  =  0.033), Var-0 (5.24  ±  1.70 ver-
sus 5.94  ±  1.62, p  =  0.031), TP-2 (5.72  ±  1.85 versus 
6.27  ±  1.71, p  =  0.043), Var-2 (5.81  ±  1.78 versus 
6.38 ±  1.61, p  =  0.030), and Var-3 (5.73 ±  1.87 versus 
6.31 ± 1.75, p = 0.037).
When using the individual components of MetS to 
evaluate their impacts on HRV indices, the four com-
ponents including WC, TG, HDL and BP exhibited lit-
tle impacts on HRV. WC(+) is only associated with 
lower VLF-0 (4.22 ± 1.75 versus 4.98 ± 1.47, p = 0.025) 
and VLF-3 (4.74 ±  2.16 versus 5.58 ±  1.53, p =  0.008). 
TG(+) is related to decreased VLF-0 (3.96 ± 1.84 versus 
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Table 1 Comparisons of demographic data between participants with and without metabolic syndrome
Total (n = 175) MetS (+) (n = 91) MetS (−) (n = 84) P-value
Age, years 65.1 ± 12.9 65.6 ± 12.3 64.6 ± 13.5 0.600
Gender, woman 100 (57.1 %) 52 (57.1 %) 48 (57.1 %) 1.000
Comorbidities
 Diabetes mellitus 55 (31.4 %) 47 (51.6 %) 8 (9.5 %) <0.001
 Hypertension 128 (73.1 %) 67 (73.6 %) 61 (72.6 %) 0.881
  Taking Beta‑blockers or ACEi/ARB 56 (32.0 %) 30 (33.0 %) 26 (31.0 %) 0.775
 Hypotension 32 (18.3 %) 13 (14.3 %) 19 (22.6 %) 0.154
  Taking midodrine 16 (9.1 %) 8 (8.8 %) 8 (9.5 %) 0.867
 Heart failure 43 (24.6 %) 22 (24.2 %) 21 (25.0 %) 0.899
 Coronary artery disease 43 (24.6 %) 27 (29.7 %) 16 (19.0 %) 0.103
 Cerebrovascular disease 23 (13.1 %) 13 (14.3 %) 10 (11.9 %) 0.641
 Peripheral arterial disease 13 (7.4 %) 5 (5.5 %) 8 (9.5 %) 0.310
Causes of uremia <0.001
 Diabetic nephropathy 55 (31.4 %) 47 (51.6 %) 8 (9.5 %)
 Hypertension 2 (1.1 %) 1 (1.1 %) 1 (1.2 %)
 Chronic GN 92 (52.6 %) 35 (38.5 %) 57 (67.9 %)
 PCKD 11 (6.3 %) 5 (5.5 %) 6 (7.1 %)
 Chronic IN 4 (2.3 %) 1 (1.1 %) 3 (3.6 %)
 Others 11 (6.3 %) 2 (2.2 %) 9 (10.7 %)
Baseline data
 Waist Circumference, cm 86.1 ± 11.0 90.1 ± 11.2 81.1 ± 8.6 <0.001
 Cardio‑Thoracic Ratio, % 0.52 ± 0.05 0.52 ± 0.05 0.52 ± 0.05 0.611
 Blood Urea Nitrogen, mg/dL 74.7 ± 20.1 73.9 ± 19.5 75.6 ± 20.7 0.578
 Creatinine, mg/dL 10.5 ± 3.5 10.9 ± 4.3 10.2 ± 2.2 0.163
 Kt/V 1.43 ± 0.24 1.37 ± 0.23 1.50 ± 0.23 <0.001
 Urea Reduction Ratio,  % 78.4 ± 54.8 81.5 ± 75.4 75.1 ± 10.1 0.441
 Calcium, mg/dL 9.1 ± 0.7 9.1 ± 0.7 9.0 ± 0.7 0.851
 Phosphate, mg/dL 4.9 ± 1.7 5.1 ± 1.6 4.7 ± 1.8 0.155
 Calcium × Phosphate, (mg/dL)2 44.6 ± 15.7 46.1 ± 14.3 43.0 ± 16.9 0.192
 Albumin, g/dL 3.8 ± 0.3 3.8 ± 0.3 3.7 ± 0.3 0.097
 Potassium, mEq/L 4.7 ± 0.8 4.8 ± 0.8 4.6 ± 0.7 0.159
 i‑PTH, ug/L 285.5 ± 481.1 204.7 ± 242.9 373.1 ± 637.5 0.025
 Hemoglobin, g/dL 9.7 ± 1.4 9.7 ± 1.4 9.7 ± 1.4 0.793
 Hematocrit, % 30.2 ± 4.2 30.0 ± 4.1 30.4 ± 4.3 0.492
 White blood cell, ×109/L 6.3 ± 2.1 6.4 ± 1.9 6.2 ± 2.4 0.532
 Total cholesterol, mg/dL 163.0 ± 35.5 167.8 ± 36.1 157.9 ± 34.3 0.066
 Triglyceride, mg/dL 157.8 ± 132.0 208.0 ± 142.0 103.5 ± 94.5 <0.001
 Low‑density lipoprotein, mg/dL 98.1 ± 30.3 105.2 ± 30.5 90.5 ± 28.3 0.001
 High‑density lipoprotein, mg/dL 35.6 ± 18.7 25.0 ± 11.6 47.2 ± 18.1 <0.001
 Sugar (postprandial), mg/dL 148.2 ± 54.9 160.5 ± 65.5 134.9 ± 36.2 0.001
 Glycated hemoglobin, % 7.1 ± 1.5 7.2 ± 1.5 6.8 ± 1.5 0.331
At the index HD
 Dry weight, kg 57.6 ± 29.6 63.5 ± 39.6 51.4 ± 7.9 0.007
 Actual UF, kg 2.22 ± 0.94 2.34 ± 0.92 2.10 ± 0.96 0.083
 %UF, % 4.02 ± 1.65 3.97 ± 1.55 4.07 ± 1.76 0.680
 MAP‑0, mmHg (MAP‑1) 90.5 ± 17.0 93.1 ± 16.9 87.7 ± 16.7 0.036
 SBP‑0, mmHg (SBP‑1) 129.0 ± 26.1 134.2 ± 23.6 123.4 ± 27.7 0.006
 DBP‑0, mmHg (DBP‑1) 71.7 ± 13.0 73.4 ± 13.2 70.0 ± 12.6 0.081
 MAP‑1, mmHg (MAP‑2) 89.9 ± 17.2 91.3 ± 17.6 88.3 ± 16.8 0.255
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4.83  ±  1.54, p  =  0.011) and Var-0 (5.16  ±  1.82 versus 
5.83  ±  1.58, p  =  0.048). Whereas both HDL(+) and 
BP(+) did not contribute to differences in HRV indices 
(Table 2).
However, the patients with FPG(+) were associated 
with significantly lower HRV indices including most indi-
ces of HRV. The comparisons of the HRV indices between 
FPG(+) and FPG(−) groups were shown in Table 3. The 
HRV indices with statistical significances included VLF-
0, LF-0, HF-0, TP-0, Var-0, VLF-1, TP-1, Var-1, VLF-2, 
TP-2, Var-2, VLF-3, LF-3, HF-3, LF/HF ratio-3, TP-3, and 
Var-3 (Table 3).
Impact on HRV: from FPG criterion
As mentioned above, the patients with FPG(+) had sig-
nificantly lower values of VLF, TP, and Var through 
HRV-0 to HRV-3, along with lower values of LF and HF 
at both HRV-0 and HRV-3, and lower LF/HF ratio at 
HRV-3 (Tables 2, 3).
In the FPG(−) group, almost all HRV indices (LF, HF, 
TP, Var, and LF/HF ratio) continuously increased dur-
ing the HD process (all p ≦ 0.001 when HRV-1 compar-
ing with HRV-2, and HRV-2 comparing with HRV-3). As 
to the rest indice, VLF, its value increased from HRV-1 
to HRV-2, but turned to decrease a little from HRV-2 to 
HRV-3 (both p ≦ 0.001). On the contrary, almost all HRV 
indices (VLF, LF, HF, TP, and Var) in the FPG(+) group 
increased initially during the HD process (from HRV-1 
to HRV-2, all p  ≦  0.001), but turned to decrease dra-
matically at the late phase of HD to the levels which were 
lower than the levels at HRV-2 (from HRV-2 to HRV-3, 
all p ≦ 0.01). Whereas the values of LF/HF ratio persis-
tently increased from HRV-1 to HRV-3 (both p values 
≦0.01). (the raw data regarding the comparisons of HRV 
in different phases of HD were not shown). As a result, 
the differences between the FPG(−) and FPG(+) groups 
of most HRV indices became larger gradually as the HD 
processed, and all the HRV indices were significantly dif-
ferent between FPG(+) and FPG(−) groups at the late 
phase of HD (HRV-3). (all p ≦ 0.001 in VLF, LF, TP, and 
Var; and ≦0.05 in HF and LF/HF ratio).
The proportion of MetS(+) in the patients with 
FPG(+) (54 out of 65 patients, 83.1  %) was significant 
higher than that in FPG(−) group (37 out of 110 patients, 
33.6 %) (p < 0.001). Then we further used MetS(+/−) to 
subcategorize patients in FPG(+) and FPG(−) groups 
and grouped them into four groups, namely, FPG(+)/
MetS(+) (n =  54), FPG(+)/MetS(−) (n =  11), FPG(−)/
MetS(+) (n = 37), and FPG(−)/MetS(−) (n = 73). Com-
pared with FPG(−)/MetS(−) group, the patients in the 
FPG(+)/MetS(+) group had lower VLF-2, TP-2, Var-2, 
VLF-3, LF-3, TP-3, and Var-3. Moreover, the patients 
in the FPG(+)/MetS(+) group had lower VLF-3, LF-3, 
TP-3, and Var-3 comparing with the FPG(−)/MetS(+) 
group (Table 3; Fig. 1).
Subgroup analysis in patients with/without diabetes 
mellitus
To further address the role of DM in affecting HRV indi-
ces in current study, we performed a subgroup analy-
sis categorizing patients by the presence or absence of 
DM. In the DM(+) subgroup (n = 65), none HRV indi-
ces were significantly different between MetS(+) and 
MetS(−) groups, while TG was the only components of 
MetS associated with differences of HRV indices. The 
TG(+) group had significantly lower VLF-0 (2.92 ± 1.44 
Values are presented as mean ± standard deviation or number (%) unless otherwise stated. P-value was calculated using Chi square test and independent student’s 
t-test. Baseline laboratory data were the pre-dialysis data obtained when patients receiving HRV measurement
ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium-channel blocker, DBP diastolic blood pressure, GN glomerulonephritis, 
IN interstitial nephritis, i-PTH intact-parathyroid hormone, MAP mean arterial pressure, PCKD polycystic kidney disease, SBP systolic blood pressure, UF ultrafiltration, 
%UF ultrafiltration divided by body weight
Table 1 continued
Total (n = 175) MetS (+) (n = 91) MetS (−) (n = 84) P-value
 SBP‑1, mmHg (SBP‑2) 125.8 ± 28.6 128.2 ± 27.6 123.2 ± 29.6 0.254
 DBP‑1, mmHg (DBP‑2) 70.8 ± 15.9 72.2 ± 16.0 69.3 ± 15.7 0.237
 HR‑1,/min (HR‑1) 74.1 ± 6.5 74.1 ± 6.2 74.1 ± 6.9 0.990
 MAP‑2, mmHg (MAP‑3) 87.5 ± 16.6 87.4 ± 17.5 87.8 ± 15.6 0.870
 SBP‑2, mmHg (SBP‑3) 123.1 ± 26.1 122.4 ± 27.8 123.9 ± 24.2 0.703
 DBP‑2, mmHg (DBP‑3) 70.2 ± 12.4 70.7 ± 12.4 69.7 ± 12.5 0.628
 HR‑2,/min (HR‑2) 75.2 ± 8.2 74.5 ± 7.7 75.9 ± 8.7 0.625
 MAP‑3, mmHg (MAP‑4) 88.5 ± 16.3 89.0 ± 17.5 88.0 ± 14.9 0.706
 SBP‑3, mmHg (SBP‑4) 125.7 ± 24.5 126.3 ± 24.7 125.0 ± 24.5 0.714
 DBP‑3, mmHg (DBP‑4) 70.7 ± 11.8 71.8 ± 11.7 69.5 ± 12.0 0.213
 HR‑3,/min (HR‑3) 75.6 ± 8.2 75.4 ± 7.4 75.9 ± 9.1 0.728
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versus 4.68  ±  1.82, p  =  0.008), TP-0 (3.54  ±  1.60 ver-
sus 5.36  ±  1.99, p  =  0.013), Var-0 (3.93  ±  1.40 ver-
sus 5.63  ±  1.95, p  =  0.014), but higher LF/HF ratio-0 
(0.96 ±  1.23 versus 0.13 ±  1.02, p =  0.049) and LF/HF 
ratio-1 (0.56 ± 1.14 versus 0.13 ± 1.15, p = 0.031) than 
the TG(−) group.
In the DM(−) subgroup (n  =  110), MetS(+) and 
MetS(−) were also not associated with differences in any 
HRV indices. The only two components with significant 
impacts on HRV indices were WC(+) which was asso-
ciated with significant lower VLF-0 (4.23 ±  1.79 versus 
5.15 ± 1.33, p = 0.017) comparing with WC(−) patients, 
and FPG(+) which was associated with lower LF/HF 
ratio-0 (0.10 ± 1.15 versus 0.26 ± 1.14, p = 0.003) than 
FPG(−) group.
From current study enrolling all 175 patients, we 
found that the existence of MetS had some impacts 
on HRV at varied phases including before and during 
HD. Among the five components, FPG(+) played a sig-
nificant and probably the major role on the influences 
of MetS. In the subsequent subgroup analysis, TG(+) 
showed its impact on HRV indices in DM(+) subgroup, 
while WC(+) and FPG(+) were exhibited to have influ-
ence on HRV in DM(−) subgroup. It’s worthwhile 
Table 2 Comparisons of the impacts on heart rate variability indices from metabolic syndrome and its five components
Values are presented as mean. p-value was calculated using independent student’s t-test. HRV-0, -1, -2, and -3 were HRV measured before HD, and at initial, middle, 
and late phases of the index hemodialysis session, respectively
↑ and ↓ denote higher and lower value in participants met the criterion comparing with those didn’t meet the criterion. #  p ≦ 0.05, ## p ≦ 0.001 in the comparison. 
The data with significant differences were expressed as mean mean ± standard deviation
Units: Ln(ms2 ) in VLF, LF, HF, TP, and Var; Ln(ratio) in LF/HF ratio
BP blood pressure, FPG fasting plasma glucose, HDL high-density lipoprotein, HF high frequency, HRV heart rate variability, LF low frequency, MetS metabolic 
syndrome, NS not significant, TG triglycerides, TP total power, Var variance of the R–R intervals, VLF very low frequency, WC waist circumference
MetS [(+) n = 91]  
vs [(−) n = 84]
Components of MetS
WC [(+) n = 79]  
vs [(−) n = 96]
BP [(+) n = 128]  
vs [(−) n = 47]
FPG [(+) n = 65]  
vs [(−) n = 110]
TG [(+) n = 63]  
vs [(−) n = 112]
HDL [(+) n = 125] 
vs [(−) n = 50]
HRV‑0
 VLF‑0 ↓# ↓# NS ↓# ↓# NS
 LF‑0 NS NS NS ↓# NS NS
 HF‑0 NS NS NS ↓# NS NS
 LF/HF‑0 NS NS NS NS NS NS
 TP‑0 ↓# NS NS ↓# NS NS
 Var‑0 ↓# NS NS ↓# ↓# NS
HRV‑1
 VLF‑1 NS NS NS ↓# NS NS
 LF‑1 NS NS NS NS NS NS
 HF‑1 NS NS NS NS NS NS
 LF/HF‑1 NS NS NS NS NS NS
 TP‑1 NS NS NS ↓# NS NS
 Var‑1 NS NS NS ↓# NS NS
HRV‑2
 VLF‑2 NS NS NS ↓# NS NS
 LF‑2 NS NS NS NS NS NS
 HF‑2 NS NS NS NS NS NS
 LF/HF‑2 NS NS NS NS NS NS
 TP‑2 ↓# NS NS ↓# NS NS
 Var‑2 ↓# NS NS ↓# NS NS
HRV‑3
 VLF‑3 NS ↓# NS ↓## NS NS
 LF‑3 NS NS NS ↓# NS NS
 HF‑3 NS NS NS ↓# NS NS
 LF/HF‑3 NS NS NS ↓# NS NS
 TP‑3 NS NS NS ↓## NS NS
 Var‑3 ↓# NS NS ↓## NS NS
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to mention that the extend of influence of FPG(+) 
on HRV was obviously decreased in the subgroup 
analyses. We considered this finding a bias from the 
imbalanced population distribution because the pro-
portion of FPG(+):FPG(−) in the DM(+) (n = 55) and 
DM(−) (n  =  120) subgroups were 100:0 and 9.1:90.9, 
respectively.
Discussion
To the best of our knowledge, current study is the first 
one to investigate the impact of MetS on HRV during HD 
in the chronic uremic population. And we demonstrated 
the serial changes of HRV indices during HD, which 
represented autonomic compensation under stress. 
The study has several main findings. First, the impact of 
Table 3 Comparisons of the heart rate variability indices of the groups
Values are presented as mean ± standard deviation. Independent student’s t-test and two-way analysis of variance (ANOVA) were used to perform comparisons 
between two groups (FPG(+) versus FPG(-)) and among four groups (FPG(+)/(-) subgrouped by MetS(+)/(-)), respectively
HRV-0, -1, -2, and -3 were HRV measured before HD, and at initial, middle, and late phases of the index hemodialysis session, respectively
Units: Ln(ms2 ) in Var, TP, VLF, LF, and HF; Ln(ratio) in LF/HF
FPG fasting plasma glucose, HRV heart rate variability, LF low frequency, MetS metabolic syndrome, NS not significant, TP total power, Var variance of the R–R intervals, 
VLF very low frequency
Total (n = 175) Comparisons between two groups [FPG(+)  
versus FPG(-)]
Comparisons among four groups [FPG(+)/MetS(+), 
FPG(+)/MetS(−), FPG(−)/MetS(+), and FPG(−)/
MetS(−)]
FPG(+) (n = 65) FPG(−) (n = 110) P-value Intergroup analysis, 
p-value
Post Hoc analysis using 
Bonferroni method, p-value
HRV‑0
 VLF‑0 4.53 ± 1.69 4.07 ± 1.77 4.80 ± 1.60 0.031
 LF‑0 3.24 ± 3.33 2.21 ± 4.73 3.85 ± 1.91 0.013
 HF‑0 3.03 ± 3.60 2.08 ± 5.26 3.59 ± 1.92 0.035
 LF/HF‑0 0.21 ± 1.20 0.13 ± 1.29 0.26 ± 1.14 0.577
 TP‑0 5.41 ± 1.80 4.87 ± 2.03 5.72 ± 1.58 0.017 0.046 NS
 Var‑0 5.60 ± 1.69 5.16 ± 1.90 5.86 ± 1.51 0.037
HRV‑1
 VLF‑1 4.94 ± 1.74 4.59 ± 1.75 5.15 ± 1.70 0.041
 LF‑1 3.49 ± 3.62 3.08 ± 2.24 3.75 ± 4.23 0.238
 HF‑1 3.19 ± 3.88 2.92 ± 1.90 3.35 ± 4.68 0.483
 LF/HF‑1 0.31 ± 1.21 0.15 ± 1.16 0.40 ± 1.23 0.196
 TP‑1 5.67 ± 1.82 5.25 ± 1.76 5.93 ± 1.82 0.015
 Var‑1 5.81 ± 1.69 5.38 ± 1.64 6.07 ± 1.67 0.009 0.045 NS
HRV‑2
 VLF‑2 5.24 ± 1.67 4.77 ± 1.56 5.52 ± 1.68 0.004 0.032 (+/+) vs (−/−), p = 0.030
 LF‑2 3.88 ± 3.64 3.37 ± 2.15 4.18 ± 4.27 0.158
 HF‑2 3.45 ± 3.93 3.14 ± 2.07 3.63 ± 4.71 0.430
 LF/HF‑2 0.43 ± 1.08 0.24 ± 1.03 0.55 ± 1.09 0.060
 TP‑2 5.98 ± 1.80 5.47 ± 1.67 6.28 ± 1.80 0.004 0.031 (+/+) vs (−/−), p = 0.024
 Var‑2 6.08 ± 1.72 5.56 ± 1.72 6.39 ± 1.65 0.002 0.017 (+/+) vs (−/−), p = 0.014
HRV‑3
 VLF‑3 5.05 ± 1.95 4.29 ± 2.04 5.49 ± 1.75 <0.001 0.001 (+/+) vs (−/−), p = 0.005
(+/+) vs (−/+), p = 0.001
 LF‑3 3.63 ± 4.30 2.29 ± 5.28 4.43 ± 3.37 0.001 0.011 (+/+) vs (−/−), p = 0.034
(+/+) vs (+/−), p = 0.020
 HF‑3 3.15 ± 4.69 2.03 ± 5.84 3.82 ± 3.72 0.015
 LF/HF‑3 0.48 ± 1.10 0.26 ± 1.24 0.61 ± 0.99 0.040 0.049 NS
 TP‑3 5.83 ± 2.04 5.02 ± 2.18 6.31 ± 1.80 <0.001 0.001 (+/+) vs (−/−), p = 0.002
(+/+) vs (−/+), p = 0.002
 Var‑3 6.00 ± 1.84 5.23 ± 1.90 6.47 ± 1.64 <0.001 <0.001 (+/+) vs (−/−), p = 0.001
(+/+) vs (−/+), p = 0.002
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Fig. 1 Plots comparing heart rate variability indices during hemodialysis among the four groups. a VLF, b LF, c HF, d TP, e Var, f LF/HF. red solid 
line FPG(+), n =  65; blue solid line FPG(‑), n = 110; red dashed line FPG(+)/MetS(+), n = 54; red dotted line FPG(+)/MetS(‑), n = 11; blue dashed line 
FPG(‑)/MetS(+), n = 37; blue dotted line FPG(‑)/MetS(‑), n = 73. HRV‑1, ‑2, and ‑3 were HRV measured at initial, middle, and late phase of the HD 
session, respectively. #, ##, ### denote p ≤ 0.05, ≤0.01, ≤0.001, respectively, between FPG(+) and FGP(‑) groups. *, **, *** denote p ≤ 0.05, ≤0.01, 
≤0.001, respectively, between two subgroups. Blue and red arrow lines respectively denote the trend of serial change of HRV in FPG(‑) and FPG(+) 
groups. $ denotes p ≤ 0.001. Units: Ln(ms2) in VLF, LF, HF, TP, and Var; Ln(ratio) in LF/HF ratio. FPG fasting plasma glucose, HF high frequency; HRV 
heart rate variability, LF low frequency,  MetS metabolic syndrome, TP total power, Var variance of the R‑R intervals, VLF very low frequency
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FPG(+) and/or MetS(+) outstood the influence of ure-
mic autonomic dysfunction. Second, FPG criterion was 
the most important component of MetS and carried the 
most powerful influence on cardiac ANS. Its impact was 
even higher than that of MetS. Third, the HRV indices of 
the FPG(−) group increased continuously throughout 
the whole HD process, while that of the FPG(+) group 
increased initially then decrease dramatically at a later 
phase of HD.
Impact on ANS: from diseased kidney
To maintain human vital functions, the ANS has to 
promptly respond to various stimuli [26]. However, sym-
pathetic overactivity which may be caused by diseased 
kidney contributes to the progression of heart and kidney 
diseases [27]. The sympathetic activity increases gradu-
ally accompanying the deterioration of renal function 
since early stage of renal dysfunction [28]. Nevertheless, 
the sympathetic activity trends to decrease in patients 
who underwent HD for a longer period and it suggests 
that sympathetic nervous functions might be affected by 
the duration of HD [29].
The HRV indices in patients with chronic kidney 
disease are lower than healthy individuals [30], and 
diminished HRV indices are indicative of cardiac ANS 
impairment and subsequent development of chronic 
kidney disease [31]. In uremic patients on maintenance 
HD, the increased LF/HF ratio with low values of both LF 
and HF is suggestive of shift of the cardiac ANS balance 
toward sympathetic predominance [27]. In the aspect 
of clinical intervention, aerobic training are found to 
increase HRV and cardiac vagal tone in both healthy and 
illed individuals [32].
Impact on HRV: from MetS and its components
Current study found that the baseline values (HRV-0) of 
almost all HRV indices (except LF/HF ratio) were signifi-
cantly lower in the patients with FPG(+) (also known as 
impaired fasting glucose (IFG)) than those with FPG(−). 
As to the serial measurement of HRV during HD, some 
indices (VLF, TP, and Var) were of significantly lower val-
ues throughout the whole HD session in FPG(+) group, 
but other indices (LF, HF, and LF/HF ratio) only showed 
the difference at late phase of HD. HD-related HRV dis-
turbance, such as hemodynamic stress or electrolyte level 
alteration, might contribute to the absence of the difference 
between FPG(+) and FPG(−) groups at earlier HD phase.
The relationships among ANS function, DM and cardi-
ovascular diseases have been addressed in several articles 
[33–35]. Both sympathetic and parasympathetic activity 
are documented to link to insulin resistance and type 2 
DM [36, 37], suggesting the critical role of abnormal glu-
cose metabolism on autonomic dysfunction. Even IFG, 
a milder form of glucose metabolism disturbance, was 
found to be associated with decreased HRV values and 
considered as an independent predictor for cardiovascular 
disease mortality in non-uremic patients after adjustment 
with other traditional cardiovascular risk factors [38]. 
The findings in current study consisted with the above-
mentioned knowledge, and further emphasized that the 
impact of FPG(+) on cardiac ANS still pronounced even 
in the presence of uremic autonomic dysfunction.
Stuckey et al. [22] reviewed 14 investigations evaluating 
the relationship between HRV and MetS in non-uremic 
population, and found that IFG might be associated with 
decreased LF and HF, increased LF/HF ratio, along with 
neural effects on TP and VLF. The impact of IFG could 
be roughly interpreted as decreasing the parasympathetic 
tone and the mixture of both sympathetic and parasympa-
thetic tone, but not yet reaching the decrease of total auto-
nomic tone. However, the results were not totally the same 
with our findings in which both sympathetic and parasym-
pathetic tone, as well as total autonomic nervous tone were 
decreased in FPG(+) patients by means of significantly 
decreased values of VLF, LF, HF, TP, and Var. The influence 
of uremic autonomic dysfunction may be responsible for 
the diverse findings between current study and others.
Among non-uremic population, the HRV values were 
of significant differences in time domain measures with 
presence of ≧1 components, and in frequency domain 
measures with presence of ≧3 components of MetS [21]. 
And the individual components of MetS played certain 
roles in affecting HRV [22]. Nonetheless, among the 
uremic patients in current study, only FPG(+) carried 
significant impact on HRV, while the rest four compo-
nents of MetS including WC, TG, HDL, and BP showed 
only little influences on HRV (Table 2). The influence of 
FPG(+) was even higher than the impact of MetS. In the 
analyses among four groups categorized by FPG(+/−) 
and MetS(+/−), patients with FPG(+) were likely to have 
lower HRV than those with FPG(−), regardless presence 
or absence of MetS (Table 3; Fig. 1). Two possible expla-
nations for the differences of influence on HRV between 
non-uremic and uremic patients were proposed. First, 
the impacts on HRV from the four components might 
be masked by the uremia-associated situation including 
uremic autonomic neuropathy. The BP issue is compli-
cated because it reflects not only ANS activity but also 
fluid status in uremic patients. The influence of lipid pro-
files on patient outcomes, and the recommendation for 
lipid management in uremic population is different from 
general population [39]. Besides, WC or obesity may only 
play a modest role in affecting ANS activity because in 
women with polycystic ovary syndrome, a entity with 
insulin resistance and sympathetic activation, the ANS 
activation is independent of metabolic disturbances and 
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obesity [40]. And visceral adiposity index may provide a 
better predictive value for cardiovascular outcomes than 
WC in HD patients [41]. The second explanation might 
be illustrated by “reverse epidemiology phenomenon” in 
uremic patients. The phenomenon refers to that the tra-
ditional cardiovascular risk factors, such as obesity, high 
BP, and dyslipidemia, turn to play protective roles of car-
diovascular system and result in lower mortality rates in 
uremic patients [42].
The serial change of HRV indices during HD: the impact 
from FPG
No matter representing sympathetic, parasympathetic, or 
total autonomic activities, all HRV indices were of lower 
mean values indicating lower ANS activities throughout 
the entire HD session in FPG(+) patients than in FPG(−) 
group in current study. Besides, different from the HRV 
measures of FPG(−) group which increased through-
out the HD process, the HRV in FPG(+) group tended 
to increase initially when the patients facing stress (HD 
with ultrafiltration), but decrease in the later phase of 
HD when the stress increased gradually. These findings 
echoed the known knowledge that DM is a risk factor 
of intradialytic hypotension [25, 43], of which one of 
the potential mechanisms is the incapability of increas-
ing both sympathetic and parasympathetic activity in 
response to the stimulus during HD [5].
In our previous work [44] evaluating the association 
between intradialytic hypotension and HRV indices in 
uremic patients, we found that the values of most HRV 
indices were consistently lower throughout the whole HD 
course in the patients with intradialytic hypotension than 
those with intradialytic hypertension. And HRV indices 
were proved as independent predictors for intradialytic 
hypotension. Interestingly and meaningfully, the plots 
comparing the serial changes of most HRV indices dur-
ing HD process between FPG(+) and FPG(−) groups in 
current study, were extremely similar with the plots com-
paring patients with intradialytic hypotension and intra-
dialytic hypertension in previous study [44]. Taken these 
two studies together, the results exhibited the pathophys-
iology and mechanism of the axis from glucose metabolic 
abnormality, through ANS disturbance, to resulting in 
intradialytic BP change.
Limitations
The current study has some limitations. First, HRV 
indices may be affected by dysrhythmia and some anti-
hypertensive agents such as beta-blockers, angiotensin 
converting enzyme inhibitors, or angiotensin II recep-
tor blockers. We had excluded patients with dysrhyth-
mia at enrollment, but we didn’t exclude patients taking 
these anti- hypertensive agents due to the restriction of 
case numbers. However, the percentage of these drugs 
usage is similar in the two groups (Table  1). Second, 
the HRV indices were only measured in the index ses-
sion of HD. The bias of sampling could not be excluded. 
Third, we only measured short-term HRV at baseline 
and three times at initial, middle, and late phases in the 
index HD. Information of 24-h long-term HRV are lack-
ing. Fourth, the sympathetic tone in our patients was 
not evaluated by some direct methods such as recording 
muscle sympathetic nerve activity or checking plasma 
norepinephrine levels. Nevertheless, these direct meth-
ods are invasive and less practically available, and their 
predictive values have yet to be determined [27]. Fifth, 
the FPG criterion didn’t exclude patients with DM in 
current study. We found that FPG(+) had significant 
impact on most HRV indices throughout entire HD 
process. But we could not further address the impact of 
varied glucose metabolism abnormalities due to the bias 
from the imbalanced population distribution in cur-
rent study. Further prospective study designed to com-
pare the impacts on HRV during HD of patients with 
DM(+), FPG(+)/DM(−), and FPG(−) is recommended.
Conclusions
In conclusion, the impact of FPG(+) and/or MetS(+) 
outstood the influence of uremic autonomic dysfunc-
tion, and FPG criterion was of the highest impact on 
HRV among the components of MetS in uremic patients. 
These results underscored the importance of interpreta-
tion and management for abnormal glucose metabolism.
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